Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma

Rhea-AI Summary

Concord Healthcare Group (NYSE: CCM) has achieved a significant medical milestone by completing China's first proton therapy treatment for choroidal malignant melanoma at its Guangzhou Concord Cancer Center. The innovative treatment, performed on July 11, 2025, offers an alternative to traditional eye removal surgery.

The center employs advanced pencil beam scanning proton therapy with real-time image guidance, enabling precise high-dose radiation delivery while protecting surrounding tissues. This breakthrough provides Chinese patients with a vision-preserving treatment option, establishing Guangzhou Concord Cancer Center as the first medical institution in China to offer this specialized treatment.

Positive

• First medical institution in China to offer proton therapy for choroidal malignant melanoma
• Advanced treatment method preserves patient vision and facial appearance, unlike traditional eye removal
• Represents significant technological advancement in cancer treatment capabilities

Negative

• None.

News Market Reaction – CCM

+5.39%

1 alert

+5.39% News Effect

On the day this news was published, CCM gained 5.39%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma.

Choroidal malignant melanoma is a common intraocular malignancy. The traditional standard treatment is enucleation, i.e. eye removal. Although enucleation can effectively control the local lesion, it will inevitably lead to permanent blindness and facial appearance changes in patients, and there are still life-threatening risks.

Guangzhou Concord Cancer Center utilizes advanced pencil beam scanning proton therapy in combination with real-time image guidance system to achieve high-dose and accurate irradiation of target area, while maximizing the protection of important neighboring structures and allowing the patient to avoid enucleation. As the first medical institution in China to offer proton therapy for this condition, Guangzhou Concord Cancer Center has filled a critical gap in the field and provided a new eye-preserving treatment option for patients with choroidal malignant melanoma.

The Company previously announced the listing of Concord Healthcare's H shares on the HKSE on January 9, 2024. The information related to Concord Healthcare's Transactions on the HKSE is accessible through the HKSE's website at www.hkexnews.hk. 

About Concord Medical

Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn.

About Concord Healthcare

Concord Healthcare is an oncology healthcare provider in China. Concord Healthcare serves both cancer patients through self-owned medical institutions and third-party medical institutions through medical equipment, software and related services. In its self-owned medical institutions, Concord Healthcare provides a full spectrum of oncology healthcare services to cancer patients across the entire care continuum, leveraging its multidisciplinary team specialists and diagnosis and treatment capabilities featuring precision radiation therapy. Through its medical equipment, software and related services, Concord Healthcare serves a widespread network of enterprise customers, primarily hospitals, with integrated oncology-related services, including primarily sales and installing of medical equipment and software, management and technical support, and operating lease.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 

View original content:https://www.prnewswire.com/news-releases/concord-healthcare-announces-completion-of-chinas-first-proton-therapy-for-choroidal-malignant-melanoma-302504414.html

SOURCE Concord Medical Services Holdings Limited

FAQ

What breakthrough treatment did Concord Healthcare (NYSE: CCM) announce in July 2025?

Concord Healthcare announced the completion of China's first proton therapy treatment for choroidal malignant melanoma at Guangzhou Concord Cancer Center on July 11, 2025.

How does CCM's proton therapy treatment differ from traditional choroidal melanoma treatment?

Unlike traditional enucleation (eye removal), CCM's proton therapy uses advanced pencil beam scanning with real-time image guidance to target the tumor while preserving vision and avoiding facial appearance changes.

What is the significance of Concord Healthcare's proton therapy achievement in China?

It marks the first time this treatment has been available in China, filling a critical gap in treatment options and providing an eye-preserving alternative for choroidal malignant melanoma patients.

Where is Concord Healthcare's proton therapy treatment being offered?

The treatment is being offered at Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare Group.